Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB’s development pipeline

BRUSSELS and SAN FRANCISCO, May 19, 2025 /PRNewswire/ — UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world’s largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical Computing Environment (SCE) for the life sciences industry. This joint effort aims to transform the legacy SCE into unified, scalable, and flexible platforms to meet the evolving demands of clinical research, regulatory compliance, and efficient data analysis.

The two companies will work together to implement a modern cloud-enabled environment that integrates diverse analytical tools, such as SAS, R, and Python, within a unified framework. This platform will leverage Domino’s expertise in cloud technologies and open-source support, combined with UCB’s deep clinical research and regulatory knowledge. Together, this effort aims to enhance research capabilities and maintain compliance with industry standards like GxP, FDA 21 CFR Part 11, and GDPR.

“At UCB, we believe that innovation thrives through collaboration, and this partnership exemplifies our commitment to evolving and pushing the boundaries of what’s possible in life sciences. By harnessing advanced technologies to modernize our statistical computing environment and combining our expertise with Domino’s cutting-edge platform, we aim to accelerate the development of innovative therapies for people living with severe diseases,” said Mike Branson, SVP, Head Biometrics and Data Science, UCB. He added, “This new SCE will embed critical metadata and workflow management to enable searchable, responsible data re-use, accelerating our cutting-edge Data Science and enabling more efficient drug development and evidence-based decision making.”

The collaboration is aligned with UCB’s broader scientific innovation strategy, which includes leveraging pathways, populations, and technology platforms to uncover the root biological causes of diseases, deepen understanding of patient populations, and accelerate R&D pipelines.

“We’re proud to partner with UCB to help patients get new therapies faster,” said Nick Elprin, CEO and co-founder of Domino Data Lab. “Together, we aim to lead the way in modernizing Statistical Computing Environments to accelerate clinical development with greater speed, flexibility, and confidence.”

The modernized SCE will bring immediate benefits to researchers, data scientists, and patients by providing streamlined access to state-of-the-art tools. Enhancing UCB’s capabilities in this way should expedite the development of differentiated therapies, offering faster, more tailored treatment options for those living with severe diseases. Additionally, the integration of advanced data science will enable more efficient clinical studies, leveraging large-scale data analysis to enhance predictions about efficacy and tolerability.

This collaboration also emphasizes UCB and Domino’s shared commitment to driving innovation across the life sciences industry. By contributing to initiatives like PHUSE, and the SCE Coalition, the partnership aims to foster open-source principles, challenge industry norms, and establish global standards for efficient and compliant statistical environments. Together, UCB and Domino are not only advancing their own operations but also paving the way for broader industry transformation.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About Domino Data Lab

Domino Data Lab empowers the largest data-driven enterprises to build and operate data science at scale. Domino’s Enterprise Data Science Platform provides an integrated experience encompassing analysis and reporting, collaboration, and governance. With Domino, global enterprises can develop better medicines, grow more productive crops, develop more competitive products, and more. Founded in 2013, Domino is backed by Sequoia Capital, Coatue Management, NVIDIA, Snowflake, and other leading investors. Learn more at domino.ai.

Investor Relations
UCB, Antje Witte
T +32.2.559.94.14
email antje.witte@ucb.com

Head of Global R&D and Business Communications
UCB, Scott Fleming
T +447702777378
email scott.fleming@ucb.com

For Domino Data Lab
David Conner
T +1 415-907-0400
email david.conner@dominodatalab.com 

Forward looking statements

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring,  retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-and-domino-data-lab-collaborate-to-modernize-statistical-computing-environment-in-life-sciences-302458732.html

SOURCE Domino Data Lab; UCB